Effect of Hemoglobin on Efficacy of CAR-T Therapy in Patients with Multiple Myeloma.
10.19746/j.cnki.issn.1009-2137.2023.03.024
- Author:
Zhi SHI
1
;
Juan CHEN
1
;
Hai-Lang XU
1
;
Hui-Juan LOU
1
;
Zi-Han CHEN
1
;
Huan-Xin ZHANG
1
;
Jiang CAO
1
;
Zhen-Yu LI
1
;
Zhi-Ling YAN
1
;
Kai-Lin XU
2
Author Information
1. Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221000, Jiangsu Province, China.
2. Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221000, Jiangsu Province, China. E-mail: lihmd@163.com.
- Publication Type:Journal Article
- Keywords:
chimeric antigen receptor T cell therapy;
efficacy;
hemoglobin;
multiple myeloma
- MeSH:
Humans;
Multiple Myeloma/drug therapy*;
Receptors, Chimeric Antigen;
Immunotherapy, Adoptive;
Treatment Outcome;
Hematologic Diseases
- From:
Journal of Experimental Hematology
2023;31(3):783-787
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the effect of hemoglobin (Hb) on the efficacy of chimeric antigen receptor T cell therapy (CAR-T) in patients with multiple myeloma (MM).
METHODS:From June 2017 to December 2020, 76 MM patients who received CAR-T therapy in the Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, with complete clinical data and evaluable efficacy, were selected as the research objects. According to the receiver operating characteristic (ROC) curve, the best cut-off value was obtained. The patients were divided into groups on the basis of Hb 105.5 g/L as the cut-off value. The age, sex, serum calcium, β2-microglobulin, serum creatinine, lactate dehydrogenase (LDH), and the influencing factors of CAR-T treatment efficacy in MM patients were analyzed.
RESULTS:Hb was an influencing factor of efficacy. Univariate analysis showed that Hb, LDH, and albumin affected the efficacy of CAR-T therapy. Multivariate analysis showed that Hb ( OR=1.039, 95% CI: 1.002-1.078) and LDH ( OR=1.014, 95% CI: 1.000-1.027) were the influencing factors for the efficacy of CAR-T therapy.
CONCLUSION:The efficacy of CAR-T therapy in MM patients with low Hb is poor, and Hb is a factor affecting the efficacy of CAR-T therapy.
